Facial soft-tissue augmentation with allogeneic human tissue collagen matrix (Dermalogen and Dermaplant).
Soft-tissue augmentation lends another dimension to facial rejuvenation. Human collagen tissue matrix offers the most physiologic solution to dermal volume depletion, structural soft-tissue malposition, and the correction of facial rhytides and various soft-tissue contour defects. Results with the use of Dermalogen have been comparable with other injectable dermal agents with the most natural effects. The absolute longevity or persistence of human tissue collagen matrix has not been established fully and depends on facial region, technique, and total volume administered. The natural fate of most related bio-materials suggest that internal dosing is required to maintain maximum effects. Dermaplant is now commercially available and is an effective agent for facial soft-tissue augmentation-nasolabial folds and lip augmentation-and secondary eyelid and nasal reconstruction. Final clinical studies will provide data on long-term persistence and relative results when compared with other acellular dermal and alloplastic grafts.
S
S
Fagien
M L
ML
Elson
D003094:Collagen / Q000008:administration & dosage*; D005145:Face / Q000601:surgery*; D005260:Female; D006801:Humans; D007267:Injections; D019651:Plastic Surgery Procedures / Q000379:methods*
D003094:Collagen